Efficacy and Tolerability of Flunarizine for the Treatment of Schizophrenia: Comparison With Haloperidol

• Status: Completed
• Trial end date: 2007-05-01
• Target enrollment: 0
• Participant gender: All

Summary

Flunarizine is a calcium channel blocker traditionally used for the treatment of vertigo and migraine. It also has the mechanism of action associated with antipsychotic activity (D2 receptor blockade), but has never been tested as such. The investigators hypothesis is that flunarizine can be an atypical antipsychotic.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ambulatório de Bipolaridade
• Collaborator: Stanley Medical Research Institute
• Treatments: Antipsychotic Agents; Flunarizine; Haloperidol; Haloperidol decanoate

Criteria

Inclusion Criteria:

• DSM-IV schizophrenic or schizoaffective patients between 18 and 55 years old with a PANSS score above 45.

Exclusion Criteria:

• Clinical disease

• Pregnancy

• Drug dependence (except for nicotine) in the past month and history of being refractory to at least 2 antipsychotics taken appropriately.